Valence8 US’s Zevra Therapeutics ZVRA Stock Holding History

Valence8 US’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-21,596	Closed	-$150K	–	62
2024 Q3	$150K	Buy	+21,596	New	+$147K	0.06%	47

Other funds holding ZVRA

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACM

Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Valence8 US's ZVRA Position: Q4 2024 in Review

Valence8 US sold out of Zevra Therapeutics (ZVRA) in Q4 2024, closing a stake of 21,596 shares — an estimated $150K sold.

Valence8 US first reported a position in ZVRA in Q3 2024 and held it in 1 quarter. The position peaked at $150K in Q3 2024. 109 funds tracked by Wall St. Rank hold ZVRA as of Q4 2024.

Valence8 US reported no remaining Zevra Therapeutics position as of Q4 2024 after selling out during the quarter.
Valence8 US sold 21,596 Zevra Therapeutics shares in Q4 2024, an estimated $150K.
Valence8 US first reported a position in Zevra Therapeutics in Q3 2024 and held it in 1 quarter.
Valence8 US's Zevra Therapeutics position peaked at $150K in Q3 2024.
109 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q4 2024.

Based on Valence8 US's 13F filing for Q4 2024, filed 12 Feb 2025.